Valneva SE (VALN) Total Current Liabilities (2020 - 2026)
Valneva SE (VALN) posted Total Current Liabilities of $110.3 million for Q1 2026, up 1.53% sequentially from $108.6 million in Q4 2025, and down 1.26% YoY from $111.7 million in Q1 2025.
Analysis
Valneva SE (VALN) Total Current Liabilities (2020 - 2026) Analysis & Trends
Valneva SE has reported Total Current Liabilities for 7 years, with the latest figure at $110.3 million in Q1 2026.
- Quarterly Total Current Liabilities fell 1.26% year-over-year to $110.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $110.3 million (down 1.26% YoY) and the FY2025 annual result came in at $108.6 million, down 12.39% from the prior year.
- Total Current Liabilities advanced to $110.3 million in Q1 2026 per VALN's latest filing, from $108.6 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $465.4 million in Q2 2022 and troughed at $108.6 million in Q4 2025.
- A 5-year average of $212.6 million and a median of $170.9 million in 2023 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2024 and 2025: Total Current Liabilities plunged 57.95% in 2024, then surged 46.75% in 2025.
- Over 5 years, Total Current Liabilities stood at $283.0 million in 2022, then sank by 39.6% to $170.9 million in 2023, then decreased by 28.37% to $122.4 million in 2024, then fell by 11.27% to $108.6 million in 2025, then rose by 1.53% to $110.3 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $110.3 million, $108.6 million, and $175.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 2.53 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 354.06 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 2.12 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.51 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 630.93 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Valneva SE | 578.54 Mn | 437.28 Mn | 1.86 Mn | 120.11 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 120.11 Mn |
| Mar 31, 2026 | 110.31 Mn |
| Dec 31, 2025 | 108.64 Mn |
| Sep 30, 2025 | 175.92 Mn |
| Jun 30, 2025 | 142.24 Mn |
| Mar 31, 2025 | 111.71 Mn |
| Dec 31, 2024 | 122.44 Mn |
| Sep 30, 2024 | 119.88 Mn |
| Jun 30, 2024 | 110.37 Mn |
| Mar 31, 2024 | 126.11 Mn |
| Dec 31, 2023 | 170.93 Mn |
| Sep 30, 2023 | 237.48 Mn |
| Jun 30, 2023 | 262.48 Mn |
| Mar 31, 2023 | 282.57 Mn |
| Dec 31, 2022 | 283.01 Mn |
| Sep 30, 2022 | 377.31 Mn |
| Jun 30, 2022 | 465.37 Mn |
| Mar 31, 2022 | 407.70 Mn |
| Dec 31, 2021 | 422.10 Mn |
| Dec 31, 2020 | 209.69 Mn |